Cidara Therapeutics (CDTX)
(Delayed Data from NSDQ)
$11.62 USD
-0.33 (-2.76%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $11.80 +0.18 (1.55%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Earnings News For CDTX
-
Cidara Therapeutics: Q2 Earnings Snapshot
-
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
-
Cidara Therapeutics: Q1 Earnings Snapshot
-
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
-
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
-
Cidara Therapeutics: Q3 Earnings Snapshot
-
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
-
Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates
-
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
-
Cidara Therapeutics: Q1 Earnings Snapshot
-
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
-
Cidara Therapeutics (CDTX) Reports Q4 Loss, Misses Revenue Estimates
-
Cidara Therapeutics: Q4 Earnings Snapshot
-
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
-
Cidara Therapeutics (CDTX) Q3 Earnings Miss Estimates
-
Cidara Therapeutics: Q3 Earnings Snapshot
-
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
-
Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates
-
Cidara Therapeutics: Q2 Earnings Snapshot
-
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
-
Cidara Therapeutics (CDTX) Reports Q1 Loss, Lags Revenue Estimates
-
Cidara Therapeutics (CDTX) Reports Q4 Loss, Tops Revenue Estimates
-
Will Cidara Therapeutics (CDTX) Report Negative Q4 Earnings? What You Should Know
-
Cidara Therapeutics (CDTX) Reports Q3 Loss, Tops Revenue Estimates
-
Cidara Therapeutics (CDTX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release